Literature DB >> 14530501

Andropause: symptom management for prostate cancer patients treated with hormonal ablation.

Carrie A Thompson1, Tait D Shanafelt, Charles L Loprinzi.   

Abstract

Andropause, or the age-related decline in serum testosterone, has become a popular topic in the medical literature over the past several years. Andropause includes a constellation of symptoms related to lack of androgens, including diminished libido, decreased generalized feeling of well-being, osteoporosis, and a host of other symptoms. The andropause syndrome is very prominent in men undergoing hormonal ablation therapy for prostate cancer. Most significant in this population are the side effects of hot flashes, anemia, gynecomastia, depression, cognitive decline, sarcopenia, a decreased overall quality of life, sexual dysfunction, and osteoporosis with subsequent bone fractures. The concept of andropause in prostate cancer patients is poorly represented in the literature. In this article, we review the current literature on the symptoms, signs, and possible therapies available to men who cannot take replacement testosterone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14530501     DOI: 10.1634/theoncologist.8-5-474

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  17 in total

Review 1.  Androgen deprivation therapy-associated vasomotor symptoms.

Authors:  Jason M Jones; Manish Kohli; Charles L Loprinzi
Journal:  Asian J Androl       Date:  2012-01-30       Impact factor: 3.285

Review 2.  Cancer in the elderly.

Authors:  Silvio Monfardini; Cristina Falci; Antonella Brunello; Sara Lonardi; Umberto Basso
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 3.  Managing the low-socioeconomic-status prostate cancer patient.

Authors:  Walter Rayford
Journal:  J Natl Med Assoc       Date:  2006-04       Impact factor: 1.798

4.  Intermittent androgen deprivation--questions remain.

Authors:  Daniel Keizman; Michael A Carducci
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

5.  Quality of sleep in patients receiving androgen deprivation therapy for prostate cancer.

Authors:  Asli Koskderelioglu; Muhtesem Gedizlioglu; Yasin Ceylan; Bulent Gunlusoy; Nilden Kahyaoglu
Journal:  Neurol Sci       Date:  2017-05-08       Impact factor: 3.307

6.  Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  Arch Intern Med       Date:  2006-02-27

Review 7.  Cognitive effects of hormone therapy in men with prostate cancer: a review.

Authors:  Christian J Nelson; Jennifer S Lee; Maria C Gamboa; Andrew J Roth
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

Review 8.  Reproductive health in the adolescent and young adult cancer patient: an innovative training program for oncology nurses.

Authors:  Susan T Vadaparampil; Nicole M Hutchins; Gwendolyn P Quinn
Journal:  J Cancer Educ       Date:  2013-03       Impact factor: 2.037

9.  Estrogenic side effects of androgen deprivation therapy.

Authors:  Theresa A Guise; Michael G Oefelein; James A Eastham; Michael S Cookson; Celestia S Higano; Matthew Raymond Smith
Journal:  Rev Urol       Date:  2007

Review 10.  Prostate cancer: psychosocial implications and management.

Authors:  Andrew J Roth; Mark I Weinberger; Christian J Nelson
Journal:  Future Oncol       Date:  2008-08       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.